menu
    • menu
    [{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Financing","leadProduct":"IKS014","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LegoChem Biosciences \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"LegoChem Biosciences \/ Orion Corporation"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"LCB71","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem Biosciences \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"LCB73","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ Iksuda","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem Biosciences \/ Iksuda"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"BostonGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LegoChem Biosciences \/ BostonGene","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem Biosciences \/ BostonGene"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LegoChem Biosciences \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem Biosciences \/ Janssen Biotech"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LegoChem Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Iksuda Therapeutics"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Iksuda Therapeutics"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"GT-00X","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ Glycotope","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Glycotope"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"LCB20A","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ Sotio","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Sotio"}]

    Find Clinical Drug Pipeline Developments & Deals by LegoChem Biosciences

    Menu

    LegoChem Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IKS014

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Orion Corporation

                            Deal Size : $410.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LegoChemBio Joins Hands with Orion to Become a Global Top ADC Company

                            Details : The net proceeds will be used to advance Lego's ADC pipeline including, LCB14, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2).

                            Product Name : IKS014

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 16, 2024

                            Lead Product(s) : IKS014

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Orion Corporation

                            Deal Size : $410.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Janssen Biotech

                            Deal Size : $1,700.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

                            Details : Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84, a Trop2 directed ADC which is currently being investigated for advanced solid tumors.

                            Product Name : LCB84

                            Product Type : Other Large Molecule

                            Upfront Cash : $100.0 million

                            December 26, 2023

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Janssen Biotech

                            Deal Size : $1,700.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BostonGene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial

                            Details : Under the collaboration, BostonGene will support the Phase I/II study of LCB84, a TROP2-directed antibody-drug conjugate (ADC), in patients with advanced cancers.

                            Product Name : LCB84

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            July 11, 2023

                            Lead Product(s) : LCB84,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BostonGene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Amgen Inc

                            Deal Size : $1,250.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the ...

                            Details : LCB’s clinical-stage ConjuAll Antibody Drug Conjugates (ADC) technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            December 23, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Amgen Inc

                            Deal Size : $1,250.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT-00X

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for u...

                            Details : Glycotope’s antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GT-00X). Targeting these specific antigens enables broad indication range, long-term treatment potential and reduced on-tar...

                            Product Name : GT-00X

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : GT-00X

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB20A

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Sotio

                            Deal Size : $1,027.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with Leg...

                            Details : Under the terms of the multi-target agreement, SOTIO will be responsible for research, development, manufacturing and commercialization of the ADC products, while LCB will support SOTIO for the research activities and the manufacturing of its products in...

                            Product Name : LCB20A

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            November 16, 2021

                            Lead Product(s) : LCB20A

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Sotio

                            Deal Size : $1,027.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Iksuda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LegoChem Biosciences and Iksuda Therapeutics Expand License Agreement for Development of Antibody-Drug Conjuga...

                            Details : Expanded agreement grants Iksuda access to LegoChem Biosciences’ next generation ADC platform for up to six targets. Iksuda also gains access to LegoChem Biosciences’ new payload, supplementing the tumour-activated payloads accessed in 2020.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Iksuda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB71

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : CStone Pharmaceuticals

                            Deal Size : $353.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate

                            Details : CStone obtains the exclusive global right to lead development and commercialization of LCB71 outside the Republic of Korea. LCB71 is a pre-clinical ADC entering into Investigational New Drug (IND) enabling studies.

                            Product Name : LCB71

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $10.0 million

                            October 29, 2020

                            Lead Product(s) : LCB71

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : CStone Pharmaceuticals

                            Deal Size : $353.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCB73

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Iksuda

                            Deal Size : $227.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LegoChem Biosciences and Iksuda Enter Licensing Agreement for Antibody Drug Conjugate Program

                            Details : LCB73 has been generated in a partnership between LCB and Swiss-based Light Chain Bioscience’s (Novimmune SA) by combining LCB’s cancer-selectively activated next-generation linker and toxin platform with Light Chain Bioscience’s proprietary antibo...

                            Product Name : LCB73

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $5.0 million

                            May 15, 2020

                            Lead Product(s) : LCB73

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Iksuda

                            Deal Size : $227.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed

                            LegoChem Biosciences

                            South Korea arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Iksuda Therapeutics

                            Deal Size : $407.3 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement

                            Details : The agreement grants Iksuda an access to Legochem Biosciences’ next-generation payload and proprietary linker to discover and advance lead ADC for difficult-to-treat tumours.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 16, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Iksuda Therapeutics

                            Deal Size : $407.3 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth